Appointments and advancements for May 5, 2026

FierceBiotechMadrigal continues MASH deal spree with $1B biobucks license for Arrowhead asset rejected by J&J

Endpoints NewsSwiss manufacturing, biotech industry so far unfazed by geopolitics

Endpoints NewsPfizer ends Trillium-related development as R&D spend jumps

Endpoints NewsMicrobiome startup raises $48M for immunotherapy and malnutrition treatments

Endpoints NewsJ&J's IBD combo fails Phase 2 studies, but will move into pivotal testing

FierceBiotechPfizer’s $2.3B Trillium bet ends in failure as remaining CD47 blocker scrapped along with T-cell engager

FierceBiotechSanofi expands AI capabilities, investing $294M to scale Toronto hub

Endpoints NewsMadrigal extends MASH deal streak with Arrowhead drug that J&J didn't want

Endpoints NewsHealthcare organizations are increasingly building their own AI tools

PharmaVoiceWhat’s at stake in Amgen’s showdown with the FDA?

BioWorldGenosco discloses GSPT protein degraders

BioWorldDeepcure develops new BRD4 BD2 inhibitors